No significant effect of 7,8-dihydroxyflavone on APP processing and alzheimer-associated phenotypes

Current Alzheimer Research

Volumn 12, Issue 1, 2015, Pages 47-52

  Zhou, Weitao ^a   Li, Xiaoyong ^a   Huang, Daochao ^a   Zhou, Weihui ^a   Li, Tingyu ^a   Song, Weihong ^a,b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

7,8 dihydroxyflavone; Alzheimer s disease; A ; Memory deficits

Indexed keywords

7,8 DIHYDROXYFLAVONE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; 6,7-DIHYDROXYFLAVONE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN (1-40); AMYLOID BETA-PROTEIN (1-42); AMYLOID BETA-PROTEIN PRECURSOR; ANTIPSYCHOTIC AGENTS; FLAVONES; PEPTIDE FRAGMENTS; PRESENILIN-1; PSEN1 PROTEIN, HUMAN; RNA, MESSENGER;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SENILE PLAQUE; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EFFECTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETICS; HEK293 CELLS; HUMANS; MAZE LEARNING; METABOLISM; MICE; MICE, TRANSGENIC; MUTATION; TIME FACTORS; TRANSFECTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPSYCHOTIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVONES; HEK293 CELLS; HUMANS; MAZE LEARNING; MICE; MICE, TRANSGENIC; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; RNA, MESSENGER; TIME FACTORS; TRANSFECTION;

EID: 84921891047     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666141218124243     Document Type: Article

References (37)

1. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3): 885-90 (1984).
2. Zhang X, Song W. The role of APP and BACE1 trafficking in APP processing and amyloid-beta generation. Alzheimers Res Ther 5(5): 46 (2013).
3. Deng Y, Wang Z, Wang R, Zhang X, Zhang S, Wu Y, et al. Amyloid-beta protein (Abeta) Glu11 is the major beta-secretase site of beta-site amyloid-beta precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Abeta Asp1 contributes to Alzheimer pathogenesis. Eur J Neurosci 37(12): 1962-9 (2013).
4. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 19(7): 739-49 (2005).
5. Sun X, He G, Song W. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J 20(9): 1369-76 (2006).
6. Zhang Z, Nadeau P, Song W, Donoviel D, Yuan M, Bernstein A, et al. Presenilins are required for gamma-secretase cleavage of beta- APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2(7): 463-5 (2000).
7. Yang Y, Wu Y, Zhang S, Song W. High glucose promotes Abeta production by inhibiting APP degradation. PLoS One 8(7): e69824 (2013).
8. Chen B, Bromley-Brits K, He G, Cai F, Zhang X, Song W. Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model. Curr Alzheimer Res 7(3): 255-61 (2010).
9. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123(1): 224-35 (2013).
10. Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205(12): 2781-9 (2008).
11. Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, et al. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 15(01): 77-90 (2012).
12. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20(4): 709-26 (1998).
13. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, et al. A selective TrkB agonist with potent neurotrophic activities by 7,8- dihydroxyflavone. Proc Natl Acad Sci USA 107(6): 2687-92 (2010).
14. Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 33(2-3): 199-227 (2000).
15. Yu Q, Chang Q, Liu X, Wang Y, Li H, Gong S, et al. Protection of spiral ganglion neurons from degeneration using small-molecule TrkB receptor agonists. J Neurosci 33(32): 13042-52 (2013).
16. Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(3): 201-6 (2000).
17. Zhang Z, Liu X, Schroeder JP, Chan CB, Song M, Yu SP, et al. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 39(3): 638-50 (2014).
18. Andero R, Heldt SA, Ye K, Liu X, Armario A, Ressler KJ. Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry 168(2): 163-72 (2011).
19. Liu X, Chan CB, Jang SW, Pradoldej S, Huang J, He K, et al. A synthetic 7,8-dihydroxyflavone derivative promotes neurogenesis and exhibits potent antidepressant effect. J Med Chem 53(23): 8274-86 (2010).
20. Choi DC, Maguschak KA, Ye K, Jang SW, Myers KM, Ressler KJ. Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc Natl Acad Sci USA 107(6): 2675-80 (2010).
21. Devi L, Ohno M. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology 37(2): 434-44 (2012).
22. Mantilla CB, Ermilov LG. The novel TrkB receptor agonist 7,8- dihydroxyflavone enhances neuromuscular transmission. Muscle Nerve 45(2): 274-6 (2012).
23. Chen C, Li XH, Zhang S, Tu Y, Wang YM, Sun HT. 7,8- dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction. Rejuvenation Res 17(3): 249-54 (2014).
24. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94(24): 13287-92 (1997).
25. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 103(49): 18727- 32 (2006).
26. Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in Alzheimer's disease model mice. J Visualized Exp (53) (2011).
27. Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W. Degradation of BACE by the ubiquitin-proteasome pathway. FASEB J 18(13): 1571-3 (2004).
28. Sun X, Wu Y, Herculano B, Song W. RCAN1 Overexpression Exacerbates Calcium Overloading-Induced Neuronal Apoptosis. PLoS One 9(4): e95471 (2014).
29. Zhang X, Wu Y, Duan X, Chen W, Zou H, Zhang M, et al. Upregulation of SET Expression by BACE1 and its Implications in Down Syndrome. Mol Neurobiol (2014).
30. Song W, Nadeau P, Yuan M, Yang X, Shen J, Yankner BA. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci USA 96(12): 6959-63 (1999).
31. Young D, Lawlor PA, Leone P, Dragunow M, During MJ. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med 5(4): 448-53 (1999).
32. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 25(6): 295- 301 (2002).
33. Mattson MP. Gene-diet interactions in brain aging and neurodegenerative disorders. Ann Intern Med 139(5 Pt 2): 441-4 (2003).
34. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58(7): 729-39 (1999).
35. Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer's disease. Biochemical and biophysical research communications 264(3): 648-51 (1999).
36. Nagahara AH, Mateling M, Kovacs I, Wang L, Eggert S, Rockenstein E, et al. Early BDNF treatment ameliorates cell loss in the entorhinal cortex of APP transgenic mice. J Neurosci 33(39): 15596-602 (2013).
37. Arancibia S, Silhol M, Moulière F, Meffre J, Höllinger I, Maurice T, et al. Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis 31(3): 316- 26 (2008).